The Quest for Nanoparticle-powered Vaccines in Cancer Immunotherapy

Overview

Journal J Nanobiotechnology

Publisher Biomed Central

Specialty Biotechnology

Date 2024 Feb 14

PMID 38355548

Authors

Zhe Sun

Hui Zhao

Li Ma

Yanli Shi

Mei Ji

Xiaodong Sun

Dan Ma

Wei Zhou

Tao Huang

Dongsheng Zhang

Affiliations

Soon will be listed here.

Abstract

Despite recent advancements in cancer treatment, this disease still poses a serious threat to public health. Vaccines play an important role in preventing illness by preparing the body's adaptive and innate immune responses to combat diseases. As our understanding of malignancies and their connection to the immune system improves, there has been a growing interest in priming the immune system to fight malignancies more effectively and comprehensively. One promising approach involves utilizing nanoparticle systems for antigen delivery, which has been shown to potentiate immune responses as vaccines and/or adjuvants. In this review, we comprehensively summarized the immunological mechanisms of cancer vaccines while focusing specifically on the recent applications of various types of nanoparticles in the field of cancer immunotherapy. By exploring these recent breakthroughs, we hope to identify significant challenges and obstacles in making nanoparticle-based vaccines and adjuvants feasible for clinical application. This review serves to assess recent breakthroughs in nanoparticle-based cancer vaccinations and shed light on their prospects and potential barriers. By doing so, we aim to inspire future immunotherapies for cancer that harness the potential of nanotechnology to deliver more effective and targeted treatments.

Citing Articles

Revolutionizing Nanovaccines: A New Era of Immunization.

Saleh M, El-Moghazy A, Elgohary A, Saber W, Helmy Y Vaccines (Basel). 2025; 13(2).

PMID: 40006673 PMC: 11860605. DOI: 10.3390/vaccines13020126.

and gastric cancer: current insights and nanoparticle-based interventions.

Shah S, Mumtaz M, Sharif S, Mustafa I, Nayila I RSC Adv. 2025; 15(7):5558-5570.

PMID: 39967885 PMC: 11834156. DOI: 10.1039/d4ra07886a.

Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges.

Wang M, Yu F, Zhang Y Mol Cancer. 2025; 24(1):26.

PMID: 39827147 PMC: 11748575. DOI: 10.1186/s12943-024-02214-5.

Innovative Nanomedicine Delivery: Targeting Tumor Microenvironment to Defeat Drug Resistance.

Meng W, Huang L, Guo J, Xin Q, Liu J, Hu Y Pharmaceutics. 2025; 16(12.

PMID: 39771528 PMC: 11728492. DOI: 10.3390/pharmaceutics16121549.

Targeting cuproptosis with nano material: new way to enhancing the efficacy of immunotherapy in colorectal cancer.

Liu X, Zhang W, Wei S, Liang X, Luo B Front Pharmacol. 2024; 15:1451067.

PMID: 39691393 PMC: 11649426. DOI: 10.3389/fphar.2024.1451067.

References

Huang X, Andina D, Ge J, Labarre A, Leroux J, Castagner B . Characterization of Calcium Phosphate Nanoparticles Based on a PEGylated Chelator for Gene Delivery. ACS Appl Mater Interfaces. 2017; 9(12):10435-10445. DOI: 10.1021/acsami.6b15925. View

Hesse C, Kollenda S, Rotan O, Pastille E, Adamczyk A, Wenzek C . A Tumor-Peptide-Based Nanoparticle Vaccine Elicits Efficient Tumor Growth Control in Antitumor Immunotherapy. Mol Cancer Ther. 2019; 18(6):1069-1080. DOI: 10.1158/1535-7163.MCT-18-0764. View

Liao Z, Huang J, Lo P, Lovell J, Jin H, Yang K . Self-adjuvanting cancer nanovaccines. J Nanobiotechnology. 2022; 20(1):345. PMC: 9316869. DOI: 10.1186/s12951-022-01545-z. View

Garcia A, Lema D . An Updated Review of ISCOMSTM and ISCOMATRIXTM Vaccines. Curr Pharm Des. 2016; 22(41):6294-6299. DOI: 10.2174/1381612822666160915161302. View

Weng J, Yang J, Wang W, Wen J, Fang M, Zheng G . Application of microneedles combined with dendritic cell-targeted nanovaccine delivery system in percutaneous immunotherapy for triple-negative breast cancer. Nanotechnology. 2023; 34(47). DOI: 10.1088/1361-6528/ace97b. View

Zhang N, Bevan M . CD8(+) T cells: foot soldiers of the immune system. Immunity. 2011; 35(2):161-8. PMC: 3303224. DOI: 10.1016/j.immuni.2011.07.010. View

Davodabadi F, Sarhadi M, Arabpour J, Sargazi S, Rahdar A, Diez-Pascual A . Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches. J Control Release. 2022; 349:844-875. DOI: 10.1016/j.jconrel.2022.07.036. View

Xiao Y, Guo G, Wang H, Peng B, Lin Y, Qu G . Curcumin/L-OHP co-loaded HAP for cGAS-STING pathway activation to enhance the natural immune response in colorectal cancer. Bioeng Transl Med. 2024; 9(1):e10610. PMC: 10771561. DOI: 10.1002/btm2.10610. View

Varypataki E, Silva A, Barnier-Quer C, Collin N, Ossendorp F, Jiskoot W . Synthetic long peptide-based vaccine formulations for induction of cell mediated immunity: A comparative study of cationic liposomes and PLGA nanoparticles. J Control Release. 2016; 226:98-106. DOI: 10.1016/j.jconrel.2016.02.018. View

10.

Su T, Liu X, Lin S, Cheng F, Zhu G . Ionizable polymeric nanocarriers for the codelivery of bi-adjuvant and neoantigens in combination tumor immunotherapy. Bioact Mater. 2023; 26:169-180. PMC: 9982230. DOI: 10.1016/j.bioactmat.2023.02.016. View

11.

Chiu D, Zhou W, Kitayaporn S, Schwartz D, Murali-Krishna K, Kavanagh T . Biomineralization and size control of stable calcium phosphate core-protein shell nanoparticles: potential for vaccine applications. Bioconjug Chem. 2012; 23(3):610-7. PMC: 3310268. DOI: 10.1021/bc200654v. View

12.

Ni Q, Xu F, Wang Y, Li Y, Qing G, Zhang Y . Nanomaterials with changeable physicochemical property for boosting cancer immunotherapy. J Control Release. 2022; 342:210-227. DOI: 10.1016/j.jconrel.2022.01.003. View

13.

Ji P, Deng X, Jin X, Zhang S, Wang J, Feng J . Fused Cytomembrane-Camouflaged Nanoparticles for Tumor-Specific Immunotherapy. Adv Healthc Mater. 2023; 12(23):e2300323. DOI: 10.1002/adhm.202300323. View

14.

Liu S, Jiang Q, Zhao X, Zhao R, Wang Y, Wang Y . A DNA nanodevice-based vaccine for cancer immunotherapy. Nat Mater. 2020; 20(3):421-430. DOI: 10.1038/s41563-020-0793-6. View

15.

Chen J, Wang B, Caserto J, Shariati K, Cao P, Pan Y . Sustained Delivery of SARS-CoV-2 RBD Subunit Vaccine Using a High Affinity Injectable Hydrogel Scaffold. Adv Healthc Mater. 2021; 11(2):e2101714. PMC: 8652948. DOI: 10.1002/adhm.202101714. View

16.

Bezbaruah R, Chavda V, Nongrang L, Alom S, Deka K, Kalita T . Nanoparticle-Based Delivery Systems for Vaccines. Vaccines (Basel). 2022; 10(11). PMC: 9694785. DOI: 10.3390/vaccines10111946. View

17.

Gandhi S, Shende P . Cyclodextrins-modified metallic nanoparticles for effective cancer therapy. J Control Release. 2021; 339:41-50. DOI: 10.1016/j.jconrel.2021.09.025. View

18.

Gholami N, Cohan R, Razavi A, Bigdeli R, Dashbolaghi A, Asgary V . Cytotoxic and apoptotic properties of a novel nano-toxin formulation based on biologically synthesized silver nanoparticle loaded with recombinant truncated pseudomonas exotoxin A. J Cell Physiol. 2019; 235(4):3711-3720. DOI: 10.1002/jcp.29265. View

19.

Mody K, Popat A, Mahony D, Cavallaro A, Yu C, Mitter N . Mesoporous silica nanoparticles as antigen carriers and adjuvants for vaccine delivery. Nanoscale. 2013; 5(12):5167-79. DOI: 10.1039/c3nr00357d. View

20.

Rizvi S, Saleh A . Applications of nanoparticle systems in drug delivery technology. Saudi Pharm J. 2018; 26(1):64-70. PMC: 5783816. DOI: 10.1016/j.jsps.2017.10.012. View